The company’s flagship product, IDx-DR, was the first autonomous AI system De Novo authorized by the FDA for the diagnosis of diabetic retinopathy and diabetic macular edema. The firm also now owns 3DermSpot, the first autonomous AI to receive FDA Breakthrough Device designation for its diagnoses of melanoma and basal cell carcinoma.